A phase 1, open-label, dose-escalation study of olaratumab as a single agent and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors.

Authors

Leo Mascarenhas

Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, University of Southern California, Los Angeles, CA

Leo Mascarenhas , Datchen Fritz Tai , Michael William Bishop , Steven G. DuBois , Theodore Willis Laetsch , Donna Elise Levy , Sada Pillay

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Phase 1 study of olaratumab as monotherapy and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors: Part A results.

First Author: Steven G. DuBois

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

ADVL1514, a phase 1 study of ABI-009 (nab-sirolimus) in pediatric patients with recurrent or refractory solid tumors, including CNS tumors as a single agent and in combination with temozolomide and irinotecan: A Children’s Oncology Group pediatric early-phase clinical trial network study.

First Author: Stuart Cramer

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors.

First Author: Kenneth Desantes

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.

First Author: Holly Jane Meany